Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg,Torasemide-IR 10 mg and Furosemide-IR 40 mg in Patients With Compensated Heart Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-02-29

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, open-label, blinded-endpoint, crossover, single dose study to compare the pharmacodynamics of Torasemide-PR 10 mg, Torasemide-IR10 mg and furosemide-IR 40 mg. 30 patients of both sexes with CHF with a maximum imbalance of 60:40% in either direction will be included in the study. Patients with compensated heart failure, grade II or III as defined by the European Society of Cardiology, with a duration of ≥ 3 months at the time of inclusion documented in the patient's record or patients who previously required diuretic therapy.

Principal variable will be the efficiency of sodium excretion that will be assessed as the ratio between the average drug-induced natriuresis and the average drug recovered in urine over 24 hours.

The difference between the efficiency of 24 hour sodium excretion following administration of torasemide PR and furosemide will be formally tested by means of a Students t-test for paired samples. The test will be two-sided at 5% significance level. Efficiency changes over time will also be assessed, however will not be subject to formal statistical testing.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure

NCT06995144

Heart Failure Edema Pulmonary Congestion +1 more

RECRUITING PHASE4

Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal

NCT06176794

Heart Failure

TERMINATED PHASE2

A Study of HRS-9057 in Patients With Heart Failure and Volume Overload

NCT06506994

Heart Failure With Volume Overload

COMPLETED PHASE1

Losartan in Decompensated Heart Failure

NCT01857999

Congestive Heart Failure Low Cardiac Output

COMPLETED PHASE4

EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan

NCT00071331

Congestive Heart Failure

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Compensated Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Torasemide PR 10 mg

Group Type EXPERIMENTAL

torasemide-PR

Intervention Type DRUG

Single oral dose of torasemide PR 10 mg

Furosemide-IR 40 mg

Group Type ACTIVE_COMPARATOR

Furosemide-IR

Intervention Type DRUG

Single oral dose of furosemide IR 40 mg

Torasemide-IR 10 mg

Group Type ACTIVE_COMPARATOR

torasemide-IR

Intervention Type DRUG

Single oral dose of torasemide IR 10 mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

torasemide-PR

Single oral dose of torasemide PR 10 mg

Intervention Type DRUG

Furosemide-IR

Single oral dose of furosemide IR 40 mg

Intervention Type DRUG

torasemide-IR

Single oral dose of torasemide IR 10 mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Able to understand the nature of the study.
2. Obtain signed informed consent form approved by the Ethics Committee of the hospital (CEIC).
3. Male and female, ≥ 18 years at the time of the informed consent signature.
4. Patients with compensated heart failure, grade II or III as defined by the European Society of Cardiology, with a duration of ≥ 3 months at the time of inclusion documented in the patient's record or patients who previously required diuretic therapy.
5. Patients with stable heart failure on drug therapy. Stable drug therapy is defined as not having introduced any new drug for heart failure within 4 weeks prior to inclusion. Drugs doses could be adjusted during the study with the exception of the diuretics
6. Lab analysis results, vital signs and ECG within normal ranges or not considered clinically significant by the investigator.
7. For women only, the patient must be:

* postmenopausal (≥ 1 year) or sterilized or,
* without risk of becoming pregnant, not lactating, have a negative pregnancy test at study entry and without intention of becoming pregnant during the study course and use effective contraception.

Postmenopausal status is defined as 12 consecutive months of spontaneous amenorrhea or confirmed by the results of follicle stimulating hormone (FSH) \> 40 mlU/mL or at least 6 months after oophorectomy (with or without hysterectomy) documented in the patients record.
8. Body weight within the normal ranges (Quetelet's index between 19 and 30) expressed as weight (kg) /height (m2).

Exclusion Criteria

1. Hospitalization due to heart failure, acute coronary syndrome, myocardial infarction, cardiac catheterization, revascularization, cardiac arrhythmia, transient ischemic attack or stroke, cardiac arrhythmia within 6 weeks prior to inclusion or major surgery including cardiac thoracic or within 8 weeks prior to inclusion.
2. Symptoms of angina at rest or with minimal activity (class III or IV, Canadian Cardiovascular Society).
3. Severe aortic or mitral stenosis or clinically significant valvular heart disease that can lead to surgery within 12 months after inclusion.
4. Hypertrophic obstructive cardiomyopathy, active myocarditis, constrictive pericarditis or clinically significant congenital heart disease.
5. If ventricular assist devices, continuous inotropic therapy or hospitalization is considered necessary in case of refractory end-stage heart failure.
6. Implementation of CRT within 3 months or cardioverter defibrillator in the 4 weeks before inclusion.
7. High probability of receiving a heart transplant within 6 months after inclusion.
8. Main organ transplant (ex. lungs, liver, kidney, heart, bone).
9. Positive surface antigen of hepatitis B, hepatitis C or HIV or a known diagnosis of AIDS.
10. Medical history or evidence of drug or alcohol abuse in the 3 months prior to inclusion.
11. Concomitant cardiovascular disease that is expected to reduce life expectancy to less than one year.
12. Scheduled routine iv infusions for heart failure (ex. inotropes, vasodilators, diuretics) or routine ultrafiltration.
13. Digoxin therapy at steady state (approximately 6 hours post-dose) exceeding 1.0 ng/mL at inclusion.
14. Chronic therapy with antiarrhythmic, antiepileptic drugs, eplerenone and espironolactone except amiodarone and beta-blockers.
15. Current intake or within 14 days prior to inclusion of a potent inhibitor of CYP2C9
16. Current intake or within 28 days prior to inclusion of a potent inducer of CYP2C9.
17. Participation, in the 60 days or 5 half lives preceding the inclusion in the study, in other clinical trial.
18. Systolic blood pressure \> 150mm Hg diastolic blood pressure \> 95 mmHg, confirmed on 2 separate visits before inclusion.
19. Heart rate in supine \> 100 beats/min after 5 minute rest or untreated symptomatic bradycardia within one month prior to inclusion.
20. Total bilirubin \> 1.5 times ULN, or ALT or AST \> 3 times ULN.
21. Estimated GFR \> 30 ml/min/1.73 m2 calculated by the modification of diet in renal disease (RD).
22. Chronic treatment with NSAIDs (\> 7 days), except aspirin \< 325 mg dose.
23. Uncontrolled insulin-dependent diabetes.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No